Drugs that contain Elagolix Sodium,estradiol,norethindrone Acetate; Elagolix Sodium
1. List of Oriahnn (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 1 month from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 3 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11459305 | ABBVIE INC | Processes for the preparation of uracil derivatives |
Nov, 2028
(5 years from now) | |
| US10881659 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(10 years from now) | |
| US11045470 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
| New Product (NP) | May 29, 2023 |
NCE-1 date: 2022-07-23
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE;ORAL
ORIAHNN (COPACKAGED) family patents
23
United States
3
New Zealand
3
Japan
3
European Union
2
Canada
1
Australia
1
EA
1
Israel
1
Croatia
1
Korea, Republic of
1
Denmark
1
Spain
1
Austria
1
Cyprus
1
Portugal
1
Poland
1
Norway
1
Germany
1
Slovenia
1
Mexico
1
Brazil
1
China
1
South Africa
2. List of Oriahnn (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
| New Product (NP) | May 29, 2023 |
NCE-1 date: 2022-07-23
Market Authorisation Date: 29 May, 2020
Treatment: NA
Dosage: CAPSULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic